Rallos

1 Comment

    • Isis Pharmaceuticals' Obesity Buster an Enormous Finding [view article]
      I don't believe that ISIS themselves are heavily pushing the anti-obesity potential of this compound as there was no statistically significant change in bodyweight in the phase 2 study (it didn't involve diet or exercise but obesity drugs in development have shown a significant change without any lifestyle intervention). I think this is partly a result of the distribution of the molecule and its particular concentration in tissues such as the liver rather than its exposure to the CNS.

      Preclinical studies have emphasised that peripheral action is mainly what contributes to the anti-diabetic effects of PTP1b inhibition while central inhibition is what's needed for the effects on bodyweight.

      Genaera appears to be the only other company with a clinical PTP1b inhibitor and it is a small-molecule central and peripheral inhibitor. It is currently in Phase 1 trials with both an anti-obesity and an anti-diabetes IND
      Jun 27 09:39 AM
Contribute an Article Become a Seeking Alpha Contributor